Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody

BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) are used for the treatment of various cancer types. However, immune-related adverse events (irAEs) occur in patients treated with ICIs. Several small-scale studies have reported the onset of irAEs and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuoka, Hiroshi, Hayashi, Takahiro, Takigami, Karen, Imaizumi, Kazuyoshi, Shiroki, Ryoichi, Ohmiya, Naoki, Sugiura, Kazumitsu, Kawada, Kenji, Sawaki, Akira, Maeda, Koutaro, Ando, Yousuke, Uyama, Ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362440/
https://www.ncbi.nlm.nih.gov/pubmed/32664888
http://dx.doi.org/10.1186/s12885-020-07142-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362440/
https://www.ncbi.nlm.nih.gov/pubmed/32664888
http://dx.doi.org/10.1186/s12885-020-07142-3

Ejemplares similares